References of "Leukemia Research"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAdequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients wih lower risk myelodysplastic syndromes
Delforge, Michel; Selleslag, Dominik; BEGUIN, Yves ULg et al

in Leukemia Research (2014), 38

Background: Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of ironoverload and associated organ damage, and death. Emerging evidence indicates that iron chelation ther ... [more ▼]

Background: Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of ironoverload and associated organ damage, and death. Emerging evidence indicates that iron chelation ther-apy (ICT) could reduce mortality and improve survival in transfusion-dependent MDS patients, especiallythose classified as International Prognostic Scoring System (IPSS) Low or Intermediate-1 (Low/Int-1).Methods: Follow-up of a retrospective study. Sample included 127 Low/Int-1 MDS patients from 28 centersin Belgium. Statistical analysis stratified by duration (≥6 versus <6 months) and quality of chelation (adequate versus weak). Results: Crude chelation rate was 63% but 88% among patients with serum ferritin ≥1000 g/L. Of the 80chelated patients, 70% were chelated adequately mainly with deferasirox (26%) or deferasirox followingdeferoxamine (39%). Mortality was 70% among non-chelated, 40% among chelated, 32% among patientschelated ≥6 m, and 30% among patients chelated adequately; with a trend toward reduced cardiacmortality in chelated patients. Overall, median overall survival (OS) was 10.2 years for chelated and 3.1years for non-chelated patients (p < 0.001). For patients chelated ≥6 m or patients classified as adequatelychelated, median OS was 10.5 years. Mortality increased as a function of average monthly transfusionintensity (HR = 1.08, p = 0.04) but was lower in patients receiving adequate chelation or chelation ≥6 m(HR = 0.24, p < 0.001). Conclusion: Six or more months of adequate ICT is associated with markedly better overall survival. Thissuggests a possible survival benefit of ICT in transfusion-dependent patients with lower-risk MDS. [less ▲]

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailFacilitating studies of cell proliferation in chronic lymphocytic leukemia
Macallan, Derek C.; Defoiche, Julien; Willems, Luc ULg

in Leukemia Research (2010), 34

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailTARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas.
Thielen, Caroline ULg; Radermacher, Vincent ULg; Trimeche, Mounir et al

in Leukemia Research (2008), 32(9), 1431-8

The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma ... [more ▼]

The current study attempts to characterize the eosinophilia associated with T-cell lymphomas and to investigate its possible relationship with the secretion of eosinophil-stimulating factors by lymphoma cells and/or intra-tumoral surrounding cells. Paraffin-embedded specimens from 50 patients diagnosed with peripheral T-cell lymphomas, either unspecified (PTCL-U, n=30) or angioimmunoblastic (AITL, n=20) were morphologically assessed for intra-tumoral eosinophilia and analyzed by immunohistochemistry using specific antibodies directed against TARC, IL-5, RANTES, and eotaxin. The AITL and PTCL-U cases contained a mean of 147+/-41 and 102+/-37 eosinophils per 10 high power fields, respectively. Thirty-two of 47 cases (68%) showed IL-5-positive lymphoma cells while 15/50 (30%) tumors showed variable staining for TARC in scattered non-lymphoid cells with dendritic morphology. TARC and IL-5-positive cases possessed significantly more eosinophils. Our data indicate that IL-5 and TARC expression highly correlate with eosinophilia in T-cell lymphomas, suggesting that these chemokines are involved in the recruitment of eosinophils into the tumors. [less ▲]

Detailed reference viewed: 29 (3 ULg)
Full Text
Peer Reviewed
See detailStem cell transplantation in ALL : a donor versus no donor comparison in the EORTC ALL-4 study
Labar, Boris; Suciu, S.; Muus, P. et al

in Leukemia Research (2007)

Detailed reference viewed: 19 (4 ULg)
Peer Reviewed
See detailExperimental Transmission Of Enzootic Bovine Leukosis To Cattle, Sheep And Goats - Infectious Doses Of Blood And Incubation Period Of The Disease
Mammerickx, M.; Portetelle, Daniel ULg; Declercq, K. et al

in Leukemia Research (1987), 11(4),

Detailed reference viewed: 31 (0 ULg)
Peer Reviewed
See detailPhenotype of thymic lymphomas in the mouse.
Greimers, Roland ULg; Rongy, Anne Michel; Defresne, Marie-Paule ULg et al

in Leukemia Research (1986), 10(7), 777-82

The MP2 cell line was established from a murine leukemia virus-induced thymic lymphoma. Half of the cells were consistently L3T4 positive and less than 5% of the cells were Lyt-2 positive. Single cell ... [more ▼]

The MP2 cell line was established from a murine leukemia virus-induced thymic lymphoma. Half of the cells were consistently L3T4 positive and less than 5% of the cells were Lyt-2 positive. Single cell cloning on the basis of the presence or absence of Lyt-2 allowed the isolation of four clones with stable phenotypes: (1) Lyt-2-, L3T4-; (2) Lyt-2+, L3T4+; (3) Lyt-2-, L3T4+; (4) Lyt2+, L3T4-. These data are discussed in relation to tumour cell heterogeneity and to normal T-cell differentiation pathways. [less ▲]

Detailed reference viewed: 34 (0 ULg)
Peer Reviewed
See detailLoss of one Ha-rasl allele in some human colorectal tumours
Lambert, S. A.; Martial, Joseph ULg; Winkler, Rose ULg

in Leukemia Research (1986), 10

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailSecond tumors and myeloproliferative diseases after Hodgkin's disease treatment
Andrien, F.; Lemaire, M.; Beguin, Yves ULg et al

in Leukemia Research (1986), 10

Detailed reference viewed: 19 (2 ULg)
Peer Reviewed
See detailEpitopes of BLV glycoprotein gp51 recognized by sera infected cattle and sheep
Bruck, Claudine; Portetelle, Daniel ULg; Mammerickx, Marc et al

in Leukemia Research (1984), 8

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailGenomic integration of bovine leukemia provirus and lack of viral RNA expression in the target cells of cattle with different responses to BLV infection.
Kettmann, Richard; Marbaix, Gérard; Cleuter, Yvette et al

in Leukemia Research (1980), 4

Detailed reference viewed: 6 (1 ULg)